Analyst Adjustment Adds Pressure to BioNTech Shares
Published on 10/11/2025 at 17:00 | Redaktion boerse-global.de
Investors in BioNTech are facing renewed uncertainty as Morgan Stanley revises its outlook for the biotechnology firm. The prominent investment bank has adjusted its price target downward for the German pharmaceutical pioneer just ahead of third-quarter earnings announcements. While maintaining a positive overall rating, this recalibration arrives during an already challenging market period that could amplify existing downward momentum.
Morgan Stanley’s research team, led by analyst Terence Flynn, has decreased their price projection from $133 to $131 per share. Despite this modest reduction, the institution continues to recommend an “Overweight” position on BioNTech stock, indicating sustained confidence in the investment’s potential. The adjustment follows comprehensive reviews of valuation methodologies and emerging data patterns within the sector.
The timing... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
